Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
Oncogenic kinases contribute to immunosuppression and modulate the tumor microenvironment in solid tumors. Increasing evidence supports the fundamental role of oncogenic kinase signaling networks in coordinating immunosuppressive tumor microenvironments. This has led to numerous studies examining th...
Main Authors: | Ryuhjin Ahn, Josie Ursini-Siegel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/5/2608 |
Similar Items
-
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
by: Liling Huang, et al.
Published: (2020-10-01) -
Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
by: Ahn, Ryuhjin, et al.
Published: (2021) -
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
by: Morgane Denis, et al.
Published: (2020-03-01) -
Can Pharmacological Receptor Tyrosine Kinase Inhibitors Sensitize Poor Outcome Breast Tumors to Immune-Based Therapies?
by: Josie eUrsini-Siegel
Published: (2013-02-01) -
Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
by: Andrew J. Bellantoni, et al.
Published: (2021-07-01)